Explore the words cloud of the MovEAID project. It provides you a very rough idea of what is the project "MovEAID" about.
The following table provides information about the project.
Coordinator |
REMOD UG (HAFTUNGSBESCHRANKT)
Organization address contact info |
Coordinator Country | Germany [DE] |
Project website | http://www.hemiparesis-therapy.com |
Total cost | 71˙429 € |
EC max contribution | 50˙000 € (70%) |
Programme |
1. H2020-EU.3.1.4. (Active ageing and self-management of health) 2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.1.6. (Health care provision and integrated care) |
Code Call | H2020-SMEINST-1-2016-2017 |
Funding Scheme | SME-1 |
Starting year | 2017 |
Duration (year-month-day) | from 2017-06-01 to 2017-11-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | REMOD UG (HAFTUNGSBESCHRANKT) | DE (BERLIN) | coordinator | 50˙000.00 |
REMOD is a young German SME with 6 employees, specialized in rehabilitation technology and rehabilitative medicine. We deliver innovativ training for chronically ill patients, and develop rehabilitation devices linked to the training content. One in five people experience a stroke at some point in their lives, and half of all strokes lead to paralysis of one side of the body, called hemiparesis. There are around 550,000 hemiparesis cases per year in the EU. Strokes cost the EU about €34.3 billion per year, of which €17 billion is spent on the treatment of hemiparesis. These costs do not include indirect costs due to incapacity to work, or unpaid care provided by relatives and friends. As such, strokes and hemiparesis are of great socioeconomic importance. Since there is no known cure for hemiparesis, treatment focuses on rehabilitation to minimise further loss of body function and reduce pain, muscle regression, or spastic paralysis due to reduced mobility. Existing rehabilitation methods includes: weak dorsiflexion, orthosis, hippotherapy and the use of therapeutic and neurorehabilitation devices. Such rehabilitation accounts for €8 billion per year of direct costs in the EU. Mobility improvements can be made with intense physiotherapy, but these improvements are not lasting due to brain damage which affects movement memory. Currently no solution exists that leads to a lasting improvement in the mobility of hemiparesis patients. We have developed, patented, and demonstrated (to TRL6) a novel wearable medical device which is embedded into a special vest to correct the posture and movement of patients suffering from hemiparesis and are now miniaturizing the device and developing the MovEAid eHealth system, containing the device and vest, for use by hemiparesis patients and health care professionals. With the help of the SME instrument, we now like to scale up our Minimal Viable Product to TRL9 and aim to bring the initial MovEAid system to the Market in 2020.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOVEAID" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MOVEAID" are provided by the European Opendata Portal: CORDIS opendata.
CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research
Read MoreSensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.
Read MoreBioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously
Read More